You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
To control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. In clinical studies the drop in intraocular pressure (IOP) appeared to decrease after Day 60 which may be associated with a progression of the disease or loss of effect of the drug. This phenomenon appears to be an individual occurence with a variable time of onset. As with any patient on maximally tolerated therapy (See Dosage & Administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if IOP rises significantly. In patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see Warnings and Precautions), and IOP control should be closely monitored.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
To control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. In clinical studies the drop in intraocular pressure (IOP) appeared to decrease after Day 60 which may be associated with a progression of the disease or loss of effect of the drug. This phenomenon appears to be an individual occurence with a variable time of onset. As with any patient on maximally tolerated therapy (See Dosage & Administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if IOP rises significantly. In patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see Warnings and Precautions), and IOP control should be closely monitored.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
To control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. In clinical studies the drop in intraocular pressure (IOP) appeared to decrease after Day 60 which may be associated with a progression of the disease or loss of effect of the drug. This phenomenon appears to be an individual occurence with a variable time of onset. As with any patient on maximally tolerated therapy (See Dosage & Administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if IOP rises significantly. In patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see Warnings and Precautions), and IOP control should be closely monitored.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.